Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: Retrospective study of a renal replacement therapy cohort
Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: Retrospective study of a renal replacement therapy cohort
复制标题
DOI：
10.1148/radiol.2451070353
复制
发表时间：
2007-10-01
期刊：
影响因子：
19.7
通讯作者：
Roditi, Giles Hannibal
中科院分区：
文献类型：
--
作者：
Collidge, Tara Anne;Thomson, Peter Campbell;Roditi, Giles Hannibal
目的：回顾性比较的频率管理和累积剂量的钆为基础的造影剂在透析依赖的患者谁没有那些谁没有发展肾源性全身fibrosis.Materials和方法：伦理委员会授予豁免的地位，这项研究，也放弃了知情同意的需要。对2000年1月1日至2006年7月1日期间在苏格兰西部接受透析的所有成人患者进行了回顾性分析。记录肾源性系统性纤维化的诊断、钆增强磁共振（MR）成像的发作和钆基造影剂的累积剂量。结果进行了分析，通过参数和非参数testing.Results：1826例患者中有14例诊断为肾源性系统性纤维化。患病和未患病患者的死亡率相似。患病和未患病患者的死亡率相似。14例肾源性系统性纤维化患者中有13例（93%）接受了钆增强MRI检查，而1812例非受累患者中有408例（22.5%）接受了钆增强MRI检查（P <0.001）。肾源性系统性纤维化患者接受更高的钆双胺中位累积剂量（0.39 vs 0.23 mmol/kg体重，P = 0.008），并且比未受影响的钆暴露对应者接受更多的钆增强MR成像。数据支持钆-在已确定的肾衰竭人群中，基于造影剂给药和肾源性系统性纤维化的发生;此外，钆双胺累积剂量与给药事件之间存在正相关。
Purpose: To retrospectively compare the frequency of administration and cumulative dose of gadolinium-based contrast agent in dialysis-dependent patients who did not those who did not develop nephrogenic systemic fibrosis.Materials and Methods: The ethics committees granted exempt status for this study and also waived the need for informed consent. A retrospective analysis was performed of all adult patients undergoing dialysis in the west of Scotland between January 1, 2000, and July 1, 2006. Diagnoses of nephrogenic systemic fibrosis, episodes of gadolinium-enhanced magnetic resonance (MR) imaging, and cumulative doses of gadolinium-based contrast agent were recorded. Outcomes were analyzed by means of parametric and non-parametric testing.Results: Fourteen of 1826 patients had a diagnosis of nephrogenic systemic fibrosis. Mortality was similar for affected and nonaffected patients. Mortality was similar for affected and nonaffected patients. Thirteen (93%) of 14 patients with nephrogenic systemic fibrosis had undergone gadolinium-enhanced MR imaging compared with 408 (22.5%) of 1812 nonaffected patients (P < .001). Patients with nephrogenic systemic fibrosis received a higher median cumulative dose of gadodiamide (0.39 vs 0.23 mmol per kilogram of body weight, P = .008) and underwent more gadolinium-enhanced MR imaging than their nonaffected gadolinium-exposed counterparts.Conclusion: The data support a positive association between gadolinium-based contrast agent administration and development of nephrogenic systemic fibrosis in the established renal failure population; in addition, there is a positive association between cumulative dose of gadodiamide used and dosing events.